Terraflos raises $3.5M Pre-Series A at $85M valuation for LATAM longevity bet
What's the deal? Terraflos, an Argentina–Uruguay biotech company, has raised a $3.5 million Pre-Series A round at an $85 million valuation. Rainforest CapitalDealroom has a profile for this one. Try Dealroom →, Swiss PampaDealroom has a profile for this one. Try Dealroom →, and Yaax CapitalDealroom has a profile for this one. Try Dealroom → led the deal, which also capitalised over $7 million in earlier strategic commitments.
What's the endgame? Terraflos builds a science platform combining biotechnology, artificial intelligence, and sustainable production of bioactives, spanning supplements, functional foods, and skincare. It operates the brands Vitalis NavitasDealroom has a profile for this one. Try Dealroom →, NutriCoDealroom has a profile for this one. Try Dealroom →, and Aurelis, and is researching roughly 35,000 plants for active ingredients.
Where the money goes: Terraflos plans to accelerate regional expansion, strengthen its scientific platform, and scale production. The company is evaluating the purchase of a laboratory and, in the final quarter of 2026, will pilot personalised supplements for 1,000 people using a ring to measure biomarkers.
The round lifts Terraflos' investment in this growth phase above $10 million. Founder and chief executive officer Facundo GarretónDealroom has a profile for this one. Try Dealroom →, a former Argentine congressman, framed the model as a new type of Latin American company. "Create a new category of Latin American company able to unite deep science with real products, consumer brands, and regional scale," he said.
Why now? Garretón argues AI is speeding the discovery of complex molecules, while Latin America holds nearly half the planet's biodiversity. "It's a spectacular moment for biotechnology," he said. The company is also close to launching G-One, a water-soluble GLP-1 powder it says is the first of its kind in Argentina.
What could go wrong? Latin America's longevity market is still nascent, and an $85 million valuation at Pre-Series A stage is ambitious for a multi-brand consumer play. Building defensible intellectual property from biodiversity research — and clearing regulatory paths for products like G-One — remains unproven at scale.
The signal: Terraflos is emerging as one of the more visible benchmarks for AI-enabled longevity and wellness platforms in Latin America. Regional investors have been increasing exposure to cannabis, nutraceuticals, and longevity-focused biotech, seeking scalable brands built on scientific platforms rather than purely local consumer bets.
Read more: La Nación
Image credit: Generated with Gemini
